最新動態

Translumina eyes 25% of stents market by 2018-end

發表日期:2018-03-12 18:45:03 作者: Qearl 標籤: 分類:

Domestic medical devices maker Translumina Therapeutics is eyeing a 25 per cent share in the Indian stents market by the 2018-end as it expands manufacturing capacity to cater the growing demand, a top company official has said.

The company currently has around 15 per cent share of the Rs 1,500 crore stents market in India, he added.

"We are looking at a 25 per cent market share of the stents market in the country by end of 2018. Currently, around seven lakh stents are implanted every year in India," Translumina Therapeutics Managing Director Gurmit Singh Chugh told PTI.

date = new Date(); date.setTime(date.getTime()+(1*24*60*60*1000)); $.cookie("dfp_cookie_article", "Y1", {expires: date,path:"/",domain: ".moneycontrol.com"});

The company had created its first drug-eluting stent from India for the world in partnership with German Heart Centre in Munich in 2011, he added.

date = new Date(); date.setTime(date.getTime()+(1*24*60*60*1000)); $.cookie("dfp_cookie_article", "Y1", {expires: date,path:"/",domain: ".moneycontrol.com"});

related news

Lenskart plans to invest USD 5 million in 3 years

Parliamentary panel asks govt to define 'shell companies' in Companies Act

The company also has had a technological partnership with Translumina GmbH to provide engineering capabilities to set up its manufacturing plant in Dehradun, which is currently being expanded to cater to the growing demand, Chugh said.

When asked how the company is planning to fund its future expansion, he said: "To scale up our international presence we need investments for which we are looking for a large private equity investor. Till now all our growth has been through internal accruals."

Betting for the decision of the National Pharmaceutical Pricing Authority (NPPA) to cap the trade margin on stents, Chugh said: "When NPPA bought down the prices of stents, they capped the margin for distributor and hospital to a total of 8 per cent , so the biggest beneficiary of the realisation of amount form the patient is the manufacturer."

This decision also effectively put an end to the bias for imported stents, he added. Translumina Therapeutics was founded by Gurmit Singh Chugh and Punita Sharma Arora in 2010.

本文來源:https://www.moneycontrol.com/news/business/translumina-eyes-25-of-stents-market-by-2018-end-2525407.html

    • 時尚編輯的真心話- Home | Facebook

      時尚編輯的真心話, 台灣台北. 90K likes. 菜鳥一隻,入行不超過十年的時尚編輯,累積很多壞話想說,也認為這個世界需要多一點真實。that\'s all! 合作請私訊.

    • 清澄的死魚眼先生‏ @POT11222449

      [轉] 被譽為「穀類中紅寶石」的紅藜,因營養價值高價格好,台東紅藜面積從3年前20公頃暴增至今年近200公頃,搶種導致供需失衡,售價從1台斤曾高達600元跌到400元,達仁鄉約15噸賣不掉,價格下滑又滯銷,農民叫苦、小農血本無歸。 旅遊業做不好 補助 農業賣不好 補助 加班費退休金不夠 e04不會做到死嗎

    • 餏ׯ~WPSIIݳܤj- Google+

      餏ׯ~WPSIIݳܤj. About. Posts. Looks like you\'ve reached the end. Looks like you\'ve reached the end. Unable to load more. Retry. Wait while ...

合作媒體:| 美體 | 健身 | 塑形 | 美容 | 髮型 | 護膚 | 香水 | 健康 | 疾病 | 食品 | 情感 | 星座 | 祝福語 | 服飾 | 搭配 |

將本站分享至:

Copyright © 2016 -Hilarious-Delicacy Moment- All Rights Reserved.